Declared Dividend • Apr 01
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 27th May 2026 Payment date: 31st July 2026 Dividend yield will be 3.5%, which is higher than the industry average of 3.0%. Sustainability & Growth The dividend has increased by an average of 1.7% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 85% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Announcement • Mar 31
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., Annual General Meeting, May 22, 2026 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., Annual General Meeting, May 22, 2026. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$15.85, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$21.92 per share. Announcement • Mar 18
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 30, 2026 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 30, 2026 Buy Or Sell Opportunity • Jan 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to HK$16.82. The fair value is estimated to be HK$21.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 100% in 2 years. Earnings are forecast to grow by 66% in the next 2 years. Buy Or Sell Opportunity • Dec 10
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 25% to HK$16.62. The fair value is estimated to be HK$20.81, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 100% in 2 years. Earnings are forecast to grow by 66% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$22.22, the stock trades at a trailing P/E ratio of 24.5x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 35% over the past year. Reported Earnings • Aug 24
First half 2025 earnings released: EPS: CN¥0.53 (vs CN¥0.40 in 1H 2024) First half 2025 results: EPS: CN¥0.53 (up from CN¥0.40 in 1H 2024). Revenue: CN¥329.7m (up 32% from 1H 2024). Net income: CN¥182.0m (up 30% from 1H 2024). Profit margin: 55% (down from 56% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Aug 12
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to HK$23.80, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 34% over the past year. Announcement • May 22
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on or Before July 31, 2025 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. at its AGM held on May 22, 2025, approved the payment of a final dividend of RMB 0.62 per Share (tax inclusive) for the year ended
December 31, 2024 (approximately RMB 214.98 million in aggregate) will be paid in Hong Kong dollars except for the dividend to be distributed to the investors of Southbound Trading (as defined in the Circular). The actual amount of final dividend for H Shares distributed in Hong Kong dollars shall be converted based on the the mean of the exchange rates of Renminbi to Hong Kong dollars as announced by the People's Bank of China during the five business days preceding the date of the AGM (May 22, 2025), that is, RMB 0.92034 to HKD 1.00, being a cash dividend
of HKD 0.673664 (tax inclusive) for every Share. The final dividend is expected to be paid on or before July 31, 2025 to the Shareholders whose names appear on the register of members of the Company on May 30, 2025. Upcoming Dividend • May 19
Upcoming dividend of CN¥0.62 per share Eligible shareholders must have bought the stock before 26 May 2025. Payment date: 31 July 2025. Payout ratio is on the higher end at 88%, and the cash payout ratio is above 100%. Trailing yield: 3.4%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (2.9%). Valuation Update With 7 Day Price Move • May 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$20.00, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 6.9% over the past year. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to HK$20.20, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 6.0% over the past year. New Risk • Apr 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Declared Dividend • Mar 31
Dividend of CN¥0.62 announced Shareholders will receive a dividend of CN¥0.62. Ex-date: 26th May 2025 Payment date: 31st July 2025 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 1.6% to bring the payout ratio under control. EPS is expected to grow by 80% over the next 2 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • Mar 30
Full year 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in FY 2023) Full year 2024 results: EPS: CN¥0.71 (up from CN¥0.44 in FY 2023). Revenue: CN¥471.6m (up 45% from FY 2023). Net income: CN¥245.6m (up 62% from FY 2023). Profit margin: 52% (up from 47% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Mar 29
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., Annual General Meeting, May 22, 2025 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., Annual General Meeting, May 22, 2025. Announcement • Mar 18
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025 Buy Or Sell Opportunity • Dec 30
Now 21% undervalued Over the last 90 days, the stock has risen 3.6% to HK$17.68. The fair value is estimated to be HK$22.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last year. Earnings per share has grown by 570%. Board Change • Dec 18
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Junwei Zheng was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Dec 10
Now 23% undervalued Over the last 90 days, the stock has risen 15% to HK$17.30. The fair value is estimated to be HK$22.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last year. Earnings per share has grown by 570%. Buy Or Sell Opportunity • Nov 20
Now 23% undervalued Over the last 90 days, the stock has risen 11% to HK$17.46. The fair value is estimated to be HK$22.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last year. Earnings per share has grown by 570%. Buy Or Sell Opportunity • Oct 08
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to HK$17.94. The fair value is estimated to be HK$23.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last year. Earnings per share has grown by 570%. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to HK$19.28, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 14x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 33% over the past year. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$14.68, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 13x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 45% over the past year. Announcement • Aug 22
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Announces Executive Changes The board of directors of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. and its subsidiaries announced that Ms. Ko Mei Ying has resigned as joint company secretary with effect from August 22, 2024. The Board further announced that, following the resignation of Ms. Ko, Mr. Li Kin Wai has been appointed as the Joint Company Secretary with effect from August 22, 2024. After the aforesaid changes, Mr. Qin Xue will continue to serve as the other Joint Company Secretary. Profile of Mr. Qin: Mr. Qin has been a deputy general manager and the chief financial officer of the Group since he joined the Group on May 28, 2021. He is responsible for overseeing the financial and accounting affairs of the Group. He is also the Joint Company Secretary. Mr. Qin joined Lepu Medical Technology (Beijing) Co., Ltd. and its subsidiaries in April 2007 and served as a manager of the financial department in Lepu Medical until September 2012. Mr. Qin served as Lepu Medical ' s manager of the financial planning department from October 2012 to June 2015, deputy director of financial management and manager of the fund management department from July 2015 to February 2018, and internal audit director from March 2018 to April 2021, respectively. Mr. Qin graduated from Capital University of Economics and Business in China with a bachelor's degree in Accounting in July 1999. He obtained qualifications as a senior accountant in July 2010 and certified management accountant (CMA) in October 2019. Profile of Mr. Li: Mr. Li is currently a senior manager of the Company Secretarial Services of Tricor Services Limited, an integrated provider offering business, corporate and investor services. Mr. Li has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Li is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 130% Cash payout ratio: 255% Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change). Announcement • Aug 12
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report first half, 2024 results on Aug 22, 2024 Announcement • Jul 26
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Announces Board and Committee Changes LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announces that Mr. Liu Daozhi ("Mr. Liu") has tendered his resignation as an independent non-executive Director with effect from July 26, 2024 in order to focus on his other business engagements. The Board announced that Mr. Zheng Junwei ("Mr. Zheng") has been appointed as an independent non-executive Director with effect from July 26, 2024. The biographical details of Mr. Zheng are set out as follows: Mr. Zheng, aged 45, is the independent non-executive Director since July 26, 2024. Before joining Company, Mr. Zheng has been committed to promoting the investment in China and international cooperation by enterprises of China Association of Enterprises with Foreign Investment ("CAEFI") members since he became the vice president of CAEFI since 2017. Since September 2018, Mr. Zheng initiated and organized 12 enterprises of CAEFI members engaging in biotechnology innovation to establish the CAEFI Biotechnology Innovation Working Committee Innovation Committee (" BIC ") and has been serving as its chairman since then. In addition, Mr. Zheng served in the Special Commissioner ' s Office of the Ministry of Commerce in Fuzhou as office manager from 2004 to 2017. Mr. Zheng graduated from the School of International Relations, National University of Defense Technology, PLA (formerly known as Nanjing Institute of International Relations in July 2003 with a bachelor's degree in international economics. Following Mr. Liu's resignation as a Director, he has also ceased to be the member of each of the remuneration committee of the Board (the "Remuneration Committee") and the nomination committee of the Board (the "Nomination Committee") and Mr. Zheng has been appointed as the member of each of the Remuneration Committee and the Nomination Committee, all with effect from July 26, 2024. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to HK$17.60, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 13x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 31% over the past year. Valuation Update With 7 Day Price Move • May 30
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$15.48, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 13x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 42% over the past year. Announcement • May 24
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Approves Final Dividend for the Year Ended December 31, 2023, Payable on or Before 30 September 2024 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. at its AGM held on May 23, 2024, approved the payment of a final dividend of RMB 0.57 per Share (tax inclusive) for the year ended December 31, 2023 (approximately RMB 197.6 million in aggregate). The final dividend is expected to be paid on or before September 30, 2024 to the Shareholders whose names appear on the register of members of the Company on May 31, 2024. Ex-dividend date is 28 May 2024. Announcement • Mar 16
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024 Announcement • Mar 01
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. Announces Board Changes The board of directors of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that Ms. Zhang Yuxin has been re-designated from an executive Director to a non-executive Director and ceased to act as the deputy general manager and the chief technology officer of the Company with effect from March 1, 2024. Ms. Zhang joined the Group in May 2011 and has been a Director of the Company since January 29, 2021. The Board also announced that the appointment of Mr. Qiu Kejin as the head of research and development department of the valve division of the Company and Mr. Hu Jinpeng as the head of research and development department of the occluder division of the Company, with effect from March 1, 2024, respectively. The biographical details of Mr. Qiu Kejin and Mr. Hu Jinpeng are set out below: Mr. Qiu Kejin, aged 36, joined the Group in June 2015. He was mainly engaged in the research and development of valve products in structural heart disease, and successively served as the research and development engineer, project manager and structural product manager. Mr. Qiu obtained a bachelor ' s degree in materials science and engineering from Harbin Engineering University in July 2009 and a doctoral degree in materials science from Harbin Engineering University in June 2015. Mr. Hu Jinpeng, aged 32, joined the Group in July 2019 as the manager of the research and development department, responsible for various research and development of cardiac occluder products and management of the project team. Mr. Hu obtained a bachelor's degree in refrigeration and cryogenic technology from the University of Shanghai for Science and Technology in July 2009 and a master's degree in thermal energy and power engineering from the University of Shanghai for Science and Technology in May 2012. Reported Earnings • Aug 24
First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.075 in 1H 2022) First half 2023 results: EPS: CN¥0.22 (up from CN¥0.075 in 1H 2022). Revenue: CN¥165.9m (up 33% from 1H 2022). Net income: CN¥76.1m (up 214% from 1H 2022). Profit margin: 46% (up from 19% in 1H 2022). New Risk • Aug 23
New major risk - Revenue and earnings growth Earnings have declined by 45% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Announcement • Aug 11
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023 LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. announced that they will report first half, 2023 results on Aug 22, 2023 Announcement • Jul 21
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Announces Executive Changes The board of directors of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. and its subsidiaries announced that Ms. Ng Ka Man ("Ms. Ng") has resigned from and Ms. Ko Mei Ying has been appointed to the following positions of the Company with effect from July 18, 2023: (i) joint company secretary; (ii) agent for the service of process and notices on behalf of the Company in Hong Kong as required under Rule 19A.13(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and (iii) authorised representative pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 3.05 of Listing Rules. After the aforesaid changes, Mr. Qin Xue ("Mr. Qin") will continue to serve as the other Joint Company Secretary. Profile of Mr. Qin: Mr. Qin has been a deputy general manager and the chief financial officer of the Group since he joined the Group on May 28, 2021. He is responsible for overseeing the financial and accounting affairs of the Group. He is also the Joint Company Secretary. Mr. Qin joined Lepu Medical Technology (Beijing) Co., Ltd. and its subsidiaries in April 2007 and served as a manager of the financial department in Lepu Medical until September 2012. Mr. Qin served as Lepu Medical ' s manager of the financial planning department from October 2012 to June 2015, deputy director of financial management and manager of the fund management department from July 2015 to February 2018, and internal audit director from March 2018 to April 2021, respectively. Mr. Qin graduated from Capital University of Economics and Business in China with a bachelor's degree in Accounting in July 1999. He obtained qualifications as a senior accountant in July 2010 and certified management accountant (CMA) in October 2019. Profile of Ms. Ko: Ms. Ko is currently a senior manager of Corporate Services of Tricor Services Limited, a global professional services provider specializing in integrated Business, Corporate and Investor Services. Ms. Ko has over 10 years ' experience in the corporate secretarial, auditing and accounting services. Ms. Ko holds a Master of Science in Professional Accounting and Corporate Governance from City University of Hong Kong, and a Bachelor degree of Commerce majoring in Accounting from Macquarie University in Australia. She is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute (HKCGI) and The Chartered Governance Institute (CGI) in the United Kingdom and Certified Practising Accountant of CPA Australia. Announcement • Jul 08
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 LEPU Scientech Medical Technology (Shanghai) Co., Ltd. provided unaudited consolidated earnings guidance for the six months ended June 30, 2023. For the period, the company expects to record a net profit attributable to the Shareholders of approximately RMB 73 million, representing an increase of around 200% as compared to the corresponding period last year. It is estimated that the non-IFRS profit is approximately RMB 85 million. The expected increase in net profit attributable to the Shareholders was mainly due to the followings: the sales volume of the Group's last generation of nitinol occluder products in the Reporting Period increased significantly compared with the corresponding period last year. This growth was driven by the broad market acceptance of these products, enabled by the Group's extensive distributor network, effective academic promotion, and strong marketing capabilities and the Group commenced sales of the MemoSorb full-biodegradable polymer-based occluder systems following the commercialization of this product, which generated an additional revenue stream for the Group in the Reporting Period as compare with the corresponding period last year. Reported Earnings • Apr 30
Full year 2022 earnings released: CN¥0.06 loss per share (vs CN¥0.19 profit in FY 2021) Full year 2022 results: CN¥0.06 loss per share (down from CN¥0.19 profit in FY 2021). Revenue: CN¥247.7m (up 11% from FY 2021). Net loss: CN¥19.8m (down 134% from profit in FY 2021). Board Change • Nov 16
Less than half of directors are independent There are 10 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Supervisor Xiaoyong Wang is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Vanessa Chan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.